LENZ Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Evert Schimmelpennink
- Full Time Employees
- 152
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 201 Lomas Santa Fe Drive Solana Beach CA United States of America 92075
- IPO Date
- Jun 25, 2021
- CIK
- 0001815776
- Website
- lenz-tx.com
- Similar Companies
- Business
- LENZ Therapeutics, Inc. is a pharmaceutical company concentrating on advancing and making available treatments to enhance sight. Its flagship product, VIZZ™ (aceclidine ophthalmic solution) 1.44%, has received U.S. FDA approval for the correction of near vision in adults experiencing presbyopia. This once-daily eye drop operates as a pupil-selective miotic, creating a pinhole effect to sharpen close-up vision for up to ten hours while minimally affecting distance vision. The company has initiated the commercial launch of VIZZ™ in the United States and has established exclusive licensing and commercialization agreements for LNZ100 in territories such as Canada, Korea, and Southeast Asia. LENZ Therapeutics is based in Solana Beach, California.
Company News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Head to Head Comparison: Eloxx Pharmaceuticals (NASDAQ:ELOX) & LENZ Therapeutics (NASDAQ:LENZ)
These beaten-down stocks could bounce back in January, if history is any guide
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
LENZ Therapeutics: Still Speculative But Priced For Disasters
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Bank of America Corp DE Boosts Stock Position in LENZ Therapeutics, Inc. $LENZ
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript
LENZ Therapeutics Q2 Earnings Call Highlights
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026